Quoin pharmaceuticals signs exclusive distribution agreement with neopharm for its lead asset, qrx003, for netherton syndrome

Ashburn, va., feb. 17, 2022 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, quoin pharmaceuticals, inc., has entered into an exclusive distribution agreement with neopharm medical supplies, an exclusive distributor for leading medical and pharma manufacturers in israel, for qrx003, the company's investigational treatment for netherton syndrome, a rare and devastating genetic disease for which there is currently no available treatment or cure.
QNRX Ratings Summary
QNRX Quant Ranking